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Nucleobase introductionGemcitabine is a ﬂuorinated nucleoside currently administered against a number of cancers. It consists of
a cytosine base and a 2-deoxy-2,2-diﬂuororibose sugar. The synthetic challenges associated with the
introduction of the ﬂuorine atoms, as well as with nucleobase introduction of 2,2-diﬂuorinated sugars,
combined with the requirement to have an efﬁcient process suitable for large scale synthesis, have
spurred signiﬁcant activity towards the synthesis of gemcitabine exploring a wide variety of synthetic
approaches. In addition, many methods have been developed for selective crystallisation of diastereo-
meric (including anomeric) mixtures. In that regard, the 2-deoxy-2,2-diﬂuororibose sugar is one of the
most investigated ﬂuorinated carbohydrates in terms of its synthesis. The versatility of synthetic meth-
ods employed is illustrative of the current state of the art of ﬂuorination methodology for the synthesis of
CF2-containing carbohydrates, and involves the use of ﬂuorinated building blocks, as well as nucleophilic
and electrophilic ﬂuorination of sugar precursors.
 2014 Published by Elsevier Ltd.1. Introduction
Gemcitabine 1 (Fig. 1) is a ﬂuorinated nucleoside analogue.1
Originally developed by Lilly, it is an anticancer drug marketed
as the HCl salt under the trade name of Gemzar (Lilly). Whilst
the market for gemcitabine continues to grow, the recent expiry
of the patent, and consequent availability of generics, have resulted
in a decrease in total revenue to below the $1 bn dollar mark
(Table 1).
In pancreatic cancer, gemcitabine is administered as the sole
agent, but in non-small cell lung cancer and bladder cancer, it is gi-
ven in combination with cisplatin. In ovarian cancer it is given be-
fore carboplatin, and in breast cancer after paclitaxel. Gemcitabine
is a prodrug; it undergoes intracellular phosphorylation to its ac-
tive diphosphate and triphosphate form, which inhibits DNA syn-
thesis leading to apoptosis.3,4
The clinical success of gemcitabine is somewhat hampered by a
short plasma half-life. GemcitabineHCl is only administered via
intravenous routes. The dosage of gemcitabine ranges from
1000–1250 mg/m2, dependent upon the type of cancer.3 The drug
is mainly metabolised by cytidine deaminases, and almost all is ex-
creted in the urine as the corresponding diﬂuorouridine species.
New approaches to increase its chemotherapeutic efﬁciency are
under investigation.5The synthesis of gemcitabine has received much attention. Fol-
lowing the original synthesis by the Eli Lilly team in 1988 featuring
a ﬂuorinated building block approach and a nucleobase introduc-
tion via displacement of an anomeric mesylate leaving group,
many modiﬁcations of this synthesis have been reported, mainly
towards improving diastereomeric ratios and/or to provide im-
proved methods for separation of the associated diastereomeric
mixtures, usually by crystallisation. In addition, alternative synthe-
ses towards the diﬂuororibose sugar featuring other methods for
ﬂuorine introduction have been described. The emphasis of this re-
view is to demonstrate the versatility of synthetic methodology
employed in the synthesis of gemcitabine, which is illustrative
for general ﬂuorinated carbohydrate synthesis. Some interesting
methodology has only been disclosed in the patent literature, of
which a selection is covered in this review. In each case only one
relevant patent has been cited. While a comprehensive coverage
of methods to achieve diastereomer separation falls outside the
scope of this review, fair attention is given to the use of particular
protecting groups to achieve selective crystallisation, given its rel-
evance in general carbohydrate chemistry. However, the many
variations described on the separation of gemcitabine anomers
(including precursors and its salts) are not covered in this review.
The original Lilly synthesis is described ﬁrst. This is then ﬁrst
followed by work towards the synthesis of 2-deoxy-2,2-diﬂuoror-
ibose, which is divided in two sections. The ﬁrst section gives an
overview of further optimisations in the ﬂuorinated building block
approach, and the second section reviews 2-deoxy-2,2-diﬂuorori-
Table 1
Gemcitabine sales ﬁgures2
Sales (in million $USD) Consumption (in kg)
12 Months ending
2012 2011 Change (%) 2012 2011 Change (%)
USA 103.6 405.5 74.5 1343 1433 6.3
EU top 5 158.8 197 19.4 1621 1678 3.4
Rest of europe 43.9 60.3 27.2 643 615 4.5
Latin america 2.4 2.3 4.3 12 10 16.5
Rest of world 416.4 446.5 6.7 3053 2808 8.7
Total 725.2 1,111.5 34.8 6673 6546 1.9
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Figure 1. Structure of gemcitabine.
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Then, an overview of the methods to introduce the nucleobase is
given, again divided in two sections. First, a number of convergent
nucleobase syntheses are listed, followed by a linear nucleobase
synthesis.
2. Gemcitabine synthesis
2.1. The original synthesis
The ﬁrst synthesis of gemcitabine 1 was developed in the Lilly
research laboratories, and was published by Hertel et al. in 1988
(Scheme 1).6
The synthesis starts from enantiopure D-glyceraldehyde (R)-2
which can be easily obtained from D-mannitol in 2 steps.7 Fluorine
introduction was achieved by a building block approach using
ethyl bromodiﬂuoroacetate. Reformatsky reaction under standard
conditions yielded a 3:1 anti/syn diastereomeric mixture, with
the Felkin-Anh product as major diastereomer. Separation of the
diastereomers syn- and anti-3 was subsequently carried out byO
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Scheme 1. Hertel et al. synHPLC (SiO2), which yielded the desired anti-3 in 65% yield. Subse-
quent deprotection using Dowex 50 led to concomitant cyclisation
to give the c-lactone 4. The remaining free alcohol groups were
then protected as TBDMS ethers and subsequent DIBAL-H medi-
ated reduction furnished the key diﬂuororibose intermediate 6 in
68% yield from anti-3.
The ﬂuorination at the ribose 2-position results in a deactiva-
tion towards nucleobase introduction, and a better anomeric leav-
ing group was required, such as the corresponding mesylate 7,
obtained from the lactol as a 1:1 anomeric mixture. Nucleobase
introduction was achieved by reaction with silylated cytidine and
TMSOTf, which required reﬂuxing in dichloroethane. Subsequent
deprotection gave gemcitabine in 50% yield, but with the undesired
a-anomer as the major diastereomer (isolated a/b ratio 4:1). The
nucleoside anomers were then separated by reverse phase-HPLC,
and the identity of the b-anomer was proven by X-ray
crystallography.
Given the strong electron withdrawing effect of the ﬂuorine
atoms in the 2-position, an SN2 displacement mechanism was ex-
pected for the nucleobase introduction. However, given a 1:1 ano-
meric mixture of mesylate 7 led to a 4:1 a/b ratio of nucleosides,
the participation of an SN1 pathway cannot be excluded.
2.2. Synthesis of diﬂuororibose—ﬂuorinated building block
approach
2.2.1. Reformatsky Reaction
The Reformatsky reaction starting from ethyl bromodiﬂuoro-
acetate, introduced by Fried et al.,8 is a well-established method
to introduce a CF2-containing moiety.9 Despite the low diastere-
oselectivity, many groups have used Hertel’s Reformatsky proce-
dure for the synthesis of 2-deoxy-2,2-diﬂuororibose.
Interestingly, the Reformatsky reaction starting from methyl iod-
odiﬂuoroacetate with D-glyceraldehyde acetonide only gave a
1.8:1 anti/syn ratio (45% yield).10 L-2-Deoxy-2-diﬂuoronucleosides
are accessible via the Reformatsky reaction with L-glyceraldehyde
acetonide,11 which is synthesised from L-gulonolactone in two
steps.12
An improvement of note was achieved when the zinc was acti-
vated with iodine, and the reaction mixture was agitated in an
ultrasonic bath under cooling (12 h, 10–12 C).13 An improved
yield of 75% of anti-3 was thus obtained after chromatography
(no ratio given at the crude reaction mixture stage).
The L-threose derivative 8 has been employed as starting mate-
rial in the synthesis of gemcitabine and homogemcitabine, also
with a Reformatsky reaction as the key step (Scheme 2).14 How-
ever, no diastereomeric ratio was given. Presumably, the recrystal-O O
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allowed separation of the diastereomers, leading to diastereomer-
ically pure 10. Protection and lactone reduction then gave the
diﬂuorolactol 11.
In addition to ethyl bromodiﬂuoroacetate as ﬂuorinated build-
ing block, 2-deoxy-2,2-diﬂuororibose has also been synthesised
using Reformatsky-type reactions with other reagents (Scheme 3).
Treatment of bromodiﬂuoroacetylene 12 with zinc, followed by
reaction with D-glyceraldehyde acetonide (R)-2, led to the addition
product 13 in 50% yield, as a 3/1 anti:syn ratio (Scheme 3, (1)).15
Diastereomeric separation using ﬂash chromatography was possi-
ble, and anti-13 was subjected to partial alkyne hydrogenation,
ozonolysis/Me2S treatment, with ﬁnal protection of the obtained
product 14 as the triacetate 15.
Alternatively, bromodiﬂuoropropene 16 has also been used for
the synthesis of 2-deoxy-2,2-diﬂuororibose (Scheme 3, (2)).16 The
addition proceeded in slightly higher diastereoselectivity, and the
diastereomers were separated by crystallisation of 14 by slow
evaporation of EtOAc. Both 14 and 15 have been used as interme-
diates for the synthesis of the lactone 4 (see Section 2.3.6).
2.2.2. Aldol reactions
A number of reports describe the reaction of glyceraldehyde
acetals with diﬂuoroacetate derived enolate species (Scheme 4).
The direct formation of lithium enolate 23 from ethyl diﬂuoroace-
tate 18 appears hampered by a dominant Claisen self-condensation
side reaction (Eq. 1).17 However, starting from t-butyl dif-
luorothioacetate 19, Weigel et al. achieved the formation of the
less reactive lithium enolate 24 (Eq. 2).17 This enolate is formed
by adding 19 to a slight excess of LDA at 78 C, and is then rapidly
(2 min) reacted with the electrophile. Nevertheless, the Claisen
condensation product is still formed in small amounts (10%), but
this could be completely avoided by forming the corresponding ke-
tene silyl O,S-acetal 25 (Eq. 3). Kobayashi et al. achieved theformation of ketene silyl acetals 26–28 via a modiﬁcation of the
Reformatsky conditions, in which a trialkylchlorosilane was in-
cluded in the reaction mixture before addition of the electrophile
(Eq. 4).10 The TMS-derivative 26 proved unstable even at room
temperature, but larger silyl groups, such as TES (27, 28) and
TBDMS (not shown) were relatively stable.
The reaction of reagents 24–28with glyceraldehyde acetals 2a–c
was shown to proceed with high to very high selectivity (Table 2).
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Aldol-type addition reactions to glyceraldehyde acetals 2
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a R = Me
b R = Et
c R = -(CH2)5-
Reactant
29 anti X = OEt; R' = H
30 anti X = OEt; R' = SiEt3
31 anti X = St-Bu; R' = H
29 syn X = OEt; R' = H
30 syn X = OEt; R' = SiEt3
31 syn X = St-Bu; R' = H
+
Entry Aldehyde Reactant Lewis-acid (equiv) Product Yield% (anti:syn) Ref.
1 2b 24 — 31b 64 (85:15) 17
2 2a 26 — 29aa 46 (9:1) 10
3 2a 27 — 30aa 74 (9:1) 10
4 2c 28 — 30c 60 (85:15) 18
5 2c 28 BF3OEt2 (1) 29c 47 (91:9) 18
6 2c 28 Me2AlCl (1) 29c 80 (78:22) 18
7 2c 28 TiCl4 (1) 29c 74 (89:11) 18
8 2c 28 Cp2TiCl2 (0.1) 30c 80 (90:10) 18
9 2c 28 Cp2TiCl2 (1) 30c 68 (>95:5) 18
10 2c 28b Cp2TiCl2 (0.1) 30c 92 (91:9) 18
11 2c 28b Cp2TiCl2 (1) 30c 84 (>95:5) 18
12 2b 25 BF3OEt2 (2) 31b 74 (95:5) 17
a X = OMe.
b Reagent derived from BrCF2COOEt (according to Eq. 4).
62 K. Brown et al. / Carbohydrate Research 387 (2014) 59–73Unfortunately, the reported selectivities resulting from different
methods are not always comparable due to the use of different
glyceraldehyde protecting groups, which are known to alter the
stereoselectivity of addition reactions to the aldehyde group.
Reaction of 2b with the lithium enolate 24 proceeded in 85:15
anti:syn ratio in moderate yield (entry 1).17 Using the ketene tri-
methyl silyl acetal 26, a low yield of 29a was obtained, if in an en-
hanced 9:1 ratio (entry 2).10 This yield was much improved by
using the corresponding 27, which gave 30a in 74% yield with
the same anti:syn ratio (entry 3).
The same methodology was applied starting from ethyl iododi-
ﬂuoroacetate 22 instead of the corresponding methyl ester 21 to
give the silyl ketene acetal 28. The resulting product 30c was ob-
tained in a lower ratio despite a cyclohexylidene acetal protected
glyceraldehyde 2c was used (entry 4).18 This lower ratio is difﬁcult
to rationalise, as better selectivities are typically obtained with this
protecting group compared to the corresponding acetonide 2a.
The reactions involving the ketene silyl acetals 26–28 (entries
2–4) are formally Mukaiyama aldol reactions, and these were
achieved without the addition of a Lewis-acid. It was thought that
the in situ formed ZnI2 was responsible for activating the aldehyde
group.
Matsumura investigated the inﬂuence of Lewis acid addition.18
In the presence of BF3OEt2, a similar anti/syn selectivity was ob-
tained, but in lower yield (entry 5). The use of Me2AlCl gave an
excellent yield, but much reduced selectivity (entry 6), while TiCl4
gave a reasonable yield with restored levels of diastereoselectivity
(entry 7). However, much improved selectivities were achievedO
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Scheme 5. Reaction of 2a with homochiral enolate derivatives.19when adding a bulky Lewis acid. Hence, with catalytic amounts
of Cp2TiCl2 (entry 8), both yield and diastereoselectivity were en-
hanced. Interestingly, a stoichiometric amount of the Lewis-acid
further improved the diastereoselectivity, but led to a decrease in
yield (entry 9). For the same process, but starting from ethyl bro-
modiﬂuoroacetate instead of ethyl iododiﬂuoroacetate, identical
diastereoselectivities but better yields were obtained (entries
10,11). However, a signiﬁcant drawback of this process for use
on large scale is the much higher molecular weight of the Lewis
acid compared to the reactants. Finally, Weigel also achieved very
high diastereoselectivities when using BF3OEt2 in the reaction
mediated by the ketene silyl O,S-acetal 25 (entry 12).17 All synO
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Scheme 6. Further functionalisation of the aldol products to diﬂuororibose
derivatives.10,18,19
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by column chromatography.
All ﬂuorinated reagents described thus far are achiral, with the
diastereoselectivities thus originating from the aldehyde chiral
centre. An interesting case of a chiral diﬂuoroacetate equivalent
32 was published, using homochiral auxiliaries (Scheme 5).19
Unfortunately, no precise diastereoselectivity was described for
the formation of 33, though the obtained product could be used
in the next step without puriﬁcation. Interestingly, reaction of an
analogous non-ﬂuorinated acetate-derived homochiral thiazolidin-
ethione reagent with 2a was reported to give a 13:1 ratio of anti-
adduct when PhBCl2/sparteine were used to effect enolisation
(not shown).20
The products of the various aldol processes were easily con-
verted to diﬂuororibose derivatives (Scheme 6). Silyl-protected
product 30c was converted to the lactone 5, an intermediate in
the Hertel synthesis.18 Alternatively, it was shown that ester
reduction prior to protection gave the 2-deoxy-2,2-diﬂuororibo-
pyranose triacetate 15.10 The conversion of 2-deoxy-2,2-diﬂuorori-
bopyranose derivatives into the required furanose forms is shown
in Section 2.3.6. Equally, reduction of the various oxazolidinone,
oxazolidine thione and thiazolidine thione auxiliaries with sodium
borohydride led to the diﬂuororibose derivative 34.19.
2.2.3. Separation of diastereomers
The separation of the diastereomers obtained from the Refor-
matsky reaction by column chromatography or HPLC is impractical
on large scale. Several modiﬁcations allowing for diastereomeric
separation by crystallisation have been developed.
2.2.3.1. Protection as benzoate esters. In 1992, Chou et al.,
also from the Lilly research laboratories, reported that protection
of the alcohol groups as benzoate esters instead of TBDMS ethers
allowed selective crystallisation of the desired 2-deoxy-2,2-diﬂu-
ororibonolactone 38 on very large scale (Scheme 7).21
The diastereomeric mixture 3, obtained by a Reformatsky reac-
tion as detailed above,6 was benzoylated using BzCl. Despite the
deactivation by the adjacent ﬂuorination, a near-quantitative yield
was obtained. Hydrolysis of the acetonide gave a mixture of diols
36, which could be cyclised by azeotropic distillation, and the
resulting lactone was fully protected using a second benzoylation
reaction to give 38 as a C3-diastereomeric mixture. At this stage,
fractional crystallisation from dichloromethane/heptane yielded
the diastereomerically pure ribonolactone derivative. This puriﬁca-
tion was reported to work even on a 2000 gallon scale.
It was mentioned that the lactone group in 38 was easily solv-
olysed, requiring great care for the crystallisation. In fact, chro-
matographic separation was not possible due to silica-gel
mediated ring opening.O
O
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Scheme 7. Synthesis of diastereomerically pure 2,2-diﬂuororibonoIn the same publication, Chou established lithium t-butoxyalu-
minium hydride as a superior lactone reducing agent to give the
lactol 34. In contrast to reaction with DIBAL-H, no over-reduction
with remaining starting material was observed.
2.2.3.2. Substituted benzoate ester protecting groups. Due
to the low yield of the recrystallisation of 38, a number of substi-
tuted dibenzoate derivatives were investigated. Cha et al. reported
the use of the 3-ﬂuorobenzoyl group as protecting group for lac-
tone 4 to achieve selective crystallisation (Scheme 8 (1)).22 Conve-
niently, the crystallisation could be achieved by just adding
additional ethyl acetate and hexane, to the ester formation reaction
mixture. Hence, starting from a 3:1 diastereomeric mixture of
Reformatsky products 3, 46% of lactone 39 was obtained in a
>98% purity.
Other substituted benzyl groups, for example p-toluoyl, were
also shown to be suitable, albeit in a lower overall yield (Scheme 8
(2)).23
Kim et al. developed a separation procedure before cyclisation
to the lactone stage (Scheme 9).24 The 3:1 diastereomeric mixture
of 3was protected as the p-phenylbenzoate 41, before ester hydro-
lysis to form the potassium salt. Removal of a third of the solvent
volume in vacuo resulted in precipitation of the desired anti diaste-
reomer 42 in 70% yield, contaminated with only 0.1% of the syn-
byproduct. Cyclisation and 5-O-benzoylation gave, after another
recrystallisation from ether/hexane, the lactone 43 free from syn-
diastereomer, in 72% yield. Reduction of 43 using Chou’s procedure
then gave 44.
A variation on this puriﬁcation was published by Xu et al., who
noted the apparent instability of the potassium salt 42.25 Instead,
TFA-mediated acetonide hydrolysis of 41, followed by lactone for-
mation through azeotropic distillation from toluene gave 43 as a
3:1 diastereomeric mixture, and puriﬁcation was achieved by
recrystallisation from toluene/hexane, leading to a 50:1 mixture
of C3-diastereomers 43 in 52% overall yield from 41 (not shown).
2.2.3.3. Protection as cinnamoyl ester. Jiang et al.26 intro-
duced the cinnamoyl protecting group for the lactone 4 to obtain
the crystalline lactone 45 (Scheme 10). Selective crystallisation
from toluene allowed isolation of 45 in both high purity (97.1%)
and ee (99.3%), in 43% yield. The lactone was then reduced and
used directly in the nucleoside introduction protocol (see below).
2.2.3.4. Protection as phenyl carbamoyl. The use of a car-
bamoyl group at the 3-position was shown to increase the
anomeric ratio in the nucleobase introduction step (see below).
While in this case the required substrate was prepared from
the corresponding dibenzoate 46, Naddaka et al. showed that the
same protecting group could be used to achieve separation of theOEt
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(Scheme 11).27 The thus obtained erythro diastereomer 47 could
then be cyclised after treatment with acid, and removal of water
by azeotropic distillation.
2.2.3.5. Derivatisation with a-methyl benzylamine. Park
et al.26 devised an alternative separation method based upon selec-
tive recrystallisation of an amide derivative. The derivatisation of
the ester 3 (Scheme 12) with an optically pure amine such as (S)-
1-phenyl ethanamine 48 produces a mixture of amides from which
the desired anti diastereomer 49 can be recrystallised from hexane
or hexane/EtOAc in 54% yield. Protection of the 3-OH as benzoate
ester 50 (or 2-naphthoyl ester) is then followed by lactonisationand further protection of the 5-OH as 2-naphthoyl (or benzoyl) es-
ter 51. The lactone is obtained in 99.8% purity (less than 0.2% of
other isomers). Reduction to the lactol is then effected with lithium
tri-t-butoxyaluminium hydride (not shown).
2.3. Synthesis of diﬂuororibose—ﬂuorination of carbohydrate
derivatives
There are a number of reports describing the synthesis of 2-
deoxy-2,2-diﬂuororibose where ﬂuorine introduction is achieved
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-ribonolactone 52.29
O
pCl-BzO
pCl-BzO
O O
pCl-BzO
O
57 58
O
TBDMSO
TBDMSO
O
O
TBDMSO
O
F
O
TBDMSO
TBDMSO
O
60 (58%)
59
61
NFSI
LiHMDS
THF, -78°C
(65%)
NFSI
LiHMDS
THF, -78°C
O
BnO
O
62
NFSI
LiHMDS
THF, -78°C
(16%)
N3
TBDPSO
O
BnO
O
N3
TBDPSO
F
F
63
Scheme 14. Electrophilic ﬂuorinations on differently protected 2-deoxylactones.29
K. Brown et al. / Carbohydrate Research 387 (2014) 59–73 65via ﬂuorination of carbohydrate or nucleoside precursors. Starting
from carbohydrate precursors, the synthesis is typically aimed at
the diﬂuororibofuranose isomer, ready for nucleobase introduc-
tion. However, some reports describe the conversion of the 2,2-
diﬂuororibopyranose form, which is the more stable isomer, to
the required furanose form.
2.3.1. Direct ﬂuorination of 2-deoxyribonolactone
Sauve and Cen developed a method to obtain the protected
diﬂuororibose 56 from the readily available 2-deoxy-D-ribonolac-
tone 52 (Scheme 13).29 This method does therefore not require
stereoselective transformations or separation of diastereomers to
obtain the desired stereochemistry at C3 and C4, which is anadvantage over many of the methods described above for the syn-
thesis of gemcitabine.30
Protection of the alcohol groups in 2-deoxy-D-ribonolactone 52
is followed by a diastereoselective electrophilic ﬂuorination of the
resulting lactone 53 with NFSI, to give the monoﬂuoroarabinolac-
tone 54 in 72% yield. The diastereoselectivity of this reaction was
attributed to the steric bulk of the O3 silyl protection preventing
a syn attack by the ﬂuorinating agent. In contrast, the same ﬂuori-
nation reaction on a corresponding 2,3-dideoxylactone proceeds
with the opposite diastereoselection, leading to the a-ﬂuorolac-
tone (not shown).31 From 54, second electrophilic ﬂuorination,
again using NFSI, furnished the diﬂuorinated lactone 55 in 71%
yield. Lactol 56 is then obtained via DIBAL reduction in excellent
yield.
The success of the ﬂuorination reaction depends on the sup-
pression of a competing elimination side reaction of the intermedi-
ate lactone lithium intermediate. As could be expected, a 3-O-ester
protecting group only gave the elimination product 58
(Scheme 14), but changing to a TBDMS ether gave 58% of the de-
sired 2-deoxy-2-ﬂuoroarabinolactone 60. However, the formation
of 61 in that reaction showed that competitive elimination is still
occurring. It is worth noting that a 3-O-benzyl ether, as in 62,
was not superior as a protecting group, which based on pKa consid-
erations (alcohol pKa = 16 versus silanol pKa = 11) is difﬁcult to
understand. However, a bulky 3-O-TIPS ether as in 53 (see
Scheme 13) proved to be a very successful substituent to achieve
successful ﬂuorination.
Instead, Sauve and Cen postulated that increasing the steric
bulk of the protecting group at 3-OH would force the ring confor-
mation such that O3 is in a pseudoequatorial position, lowering its
propensity for elimination. An MM2 minimisation of the lithium
enolate of 53 conﬁrmed this.
2.3.2. Synthesis from D-ribose
A short synthesis of a 2-deoxy-2,2-diﬂuororibose precursor
was reported by Gong (Scheme 15).32 The commercially available
1-O-acetyl-2,3,5-tri-O-benzoyl-b-d-ribofuranose 64 was subjected
to an anomeric bromination/ester migration sequence to give the
1,3,5-tri-O-benzoyl-a-D-ribofuranose 65.33 Oxidation of the free
2-OH group to the ketone then allowed for ﬂuorination with a
DAST-HFEt3N mixture to give 67, which was then used directly
for the nucleobase introduction. The use of DAST alone in the
ﬂuorination step was reported to give low yields.
2.3.3. Synthesis from D-mannose
The group of Castillón has described two approaches for the
synthesis of 2-deoxy-2,2-diﬂuororibose, both relying on the direct
ﬂuorination of a 3-ulose intermediate.34 The ﬁrst approach started
from methyl-a-D-mannopyranoside 68, which was converted to
the required ulose 70 using a known procedure (Scheme 16).35
Reaction of 70 with DAST gave the 2,2-diﬂuorinated 71 in 70%
yield. The 4,6-di-O-benzylidene acetal was then hydrolysed to al-
low the desired benzoate protection. Conversion of the anomeric
methyl acetal to the corresponding selenide, followed by oxidative
elimination gave the glycal 73. Reductive ozonolysis and subse-
quent hydrolysis then furnished the desired protected diﬂuorori-
bose 34.
2.3.4. Synthesis from D-glucose
A second approach described by Castillón relied on ﬂuorination
of ulose 74, still oxygenated in the 2-position (Scheme 17).34
The ulose 74was synthesised fromD-glucose in 4 steps, involving
sequential protections of the anomeric position, the 4- and
6-OH positions, and ﬁnally the 2-OH position (not shown).
Oxidation of the remaining 3-OH then gave 74, followed by
DAST-mediated ﬂuorination to give 75. The benzylidene acetal
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benzoates, to give the diﬂuorosugar 76 in 90% yield. Hydrogenation
removed the benzyl protecting groups in 59% yield to give 77,
enabling sodium periodate mediated cleavage of the diol. Subse-
quent hydrolysis of residual 4-O-formate ester by methanolic NH3furnished the desired protected diﬂuororibose 34 in 43% yield. It
was reported that when the methyl glycoside derivative was used,
anomeric deprotection was low-yielding.
Interestingly, the DAST-mediated ﬂuorination of 3-uloses was
ﬁrst studied in benzene, which gave lower yields of the corre-
sponding diﬂuorosugars (40–48%, not shown). This was found to
be due in part to the formation of the Grob-fragmentation product
83, the proposed mechanism of which is shown in Scheme 18.36
2.3.5. Synthesis from 1,6-anhydro-b-D-glucose
Gong also reported the synthesis of 2-deoxy-2,2-diﬂuororibose
from 1,6-anhydro-b-D-glucose 84 (Scheme 19).37 Selective protec-
tion as the 2,4-di-O-TMS ether gave a near quantitative yield of
85, which was oxidised with Dess-Martin periodinane. The silyl
ethers were subsequently removed to give ulose 86. Reprotection
of O2 and O4 as methyl ethers allowed for the ﬂuorination of ulose
87 with DAST in the presence of DMPU-HF. The use of both DAST
and DMPU-HF not only gave an increased yield of the diﬂuorosugar
88, but also allowed the reaction time to be signiﬁcantly shortened.
Hydrolysis in strong acidic medium gave 3-deoxy-3,3-diﬂuoroglu-
cose 89. Periodate oxidation was reported to selectively cleave the
C1–C2 bond to give 2-deoxy-2,2-diﬂuororibose 14 (shown here in
the pyranose form).
2.3.6. Conversion of 2-deoxy-2,2-diﬂuororibopyranose to the
furanose isomer
Given the higher stability of pyranoses compared to the corre-
sponding furanoses, pentose derivatives with unprotected 4- and
5-OH groups typically adopt the pyranose form. While unprotected
2-deoxy-2,2-diﬂuororibose can be found depicted in the literature
both as the pyranose and the furanose forms, it is generally ac-
cepted that also in this case, the pyranose form is the most stable
tautomer. While the structure of 2-deoxy-2,2-diﬂuororibopyra-
nose was reported to be conﬁrmed by X-ray crystallography,38
the structure has not been deposited to the Cambridge Crystallo-
graphic database.
The isomerisation of the pyranose to the corresponding fura-
nose form can be achieved, generally, by certain alcohol protection
protocols, and this has been demonstrated in the context of gem-
citabine synthesis.
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isomer 90 (Scheme 20, (1)).39 The isomerisation is possible due
to the presence of a pyranose–furanose equilibrium in solution
phase, and the much faster tritylation of primary alcohols com-
pared to secondary ones. A crude yield of 47% was reported, which,
after puriﬁcation by ﬂash chromatography dropped to 19%.
A similar isomerisation was achieved by an acetylation reaction
(Scheme 20, (2)). Though there are many reports describing the
acetylation of 2-deoxy-2,2-diﬂuororibopyranose 14 to give the cor-
responding triacetate in the pyranose form,10,15,38 the outcome re-
ported here, with slow addition of AcCl, can be understood by
initial acetylation of the primary 5-OH group before reaction of
the secondary OH groups. Unfortunately no spectral details of 91
were provided, though subsequent conversion to gemcitabine is
clearly proof of structure.
As mentioned before, a c-lactone is more stable than a d-lac-
tone, which has already been exploited in the ﬁrst Hertel synthesis
of gemcitabine. In a patent describing a diﬂuororibose recycling
method starting from the undesired gemcitabine a-anomer, Naga-
rajan published two oxidation protocols in which the diﬂuoropyr-
anose is converted to the corresponding c-lactone 4 (Scheme 21) in
excellent yield.38 The lactone is water-soluble, and was obtained in
pure form after several lyophilisation cycles.
2.3.7. Fluorination of nucleoside derivatives
Gemcitabine has also been obtained via ﬂuorination of 2-keto
nucleoside derivatives. Kjell reported a synthesis from cytidine
(Scheme 22).40 Full protection of all alcohol groups as well as the
cytosine amino group, followed by regioselective deprotection at
the 20-position gave 92, which could then be oxidised and ﬂuori-
nated with DAST and HF-pyridine. As in the Chen synthesis,37 DAST
alone does not effect the ﬂuorination, in this instance the reaction
does not proceed in the absence of HF-pyridine. Finally NaOMe
mediated deprotection furnishes gemcitabine.
An interesting synthesis via ﬂuorination of a nucleoside deriva-
tive was reported by Noe et al. (Scheme 23).14 Starting from 1,2-
isopropylidene allofuranose 93, protective group manipulations
led to 94, which acted as substrate for the nucleobase introduction.
No anomeric ratio was given, but presumably chromatography
after subsequent selective removal of the phenoxyacetate group
led to anomerically pure product, which after oxidation gave 95.
Fluorination, again with a DAST-HFpy mixture was then followed
by full deprotection to give homogemcitabine. Gemcitabine was
then obtained by periodate cleavage of the side-chain diol, fol-
lowed by reduction.
2.4. Nucleobase introduction—direct coupling
Nucleobase addition methods, such as the Hilbert-Johnson and
Vorbruggen protocols, are disfavoured in the synthesis of gemcita-
bine due to the highly electron withdrawing nature of the diﬂuoro
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subject to extensive optimisation, not only with regard to yield/
conversion, but also to anomeric selectivity. The selected coverage
in this review is focused on the various donor systems that have
been used to achieve nucleobase introduction. Many crystallisation
protocols have been described in order to obtain gemcitabine, or its
hydrochloride salt, in high anomeric purity. However, though some
examples of crystallisation protocols are given, comprehensive
coverage of the anomeric puriﬁcation protocols falls outside the
scope of this review.
2.4.1. Mesylate leaving group
In the original Hertel synthesis (Scheme 1),6 nucleobase intro-
duction was achieved by displacement of a mesylate leaving group
by a disilylated cytosine nucleophile, on a 3,5-disilylated (TBDMS)
diﬂuororibose sugar. Clearly the obtained anomeric selectivity
(favouring the undesired a-anomer in a 4:1 ratio), was unsatisfac-
tory. Interestingly, the anomeric selectivity was improved (to 1:1)
when the mesylate of the corresponding 3,5-di-O-triisopropylsilyl
(TIPS) protected diﬂuororobose sugar was used.30 This was also
the ratio obtained by Chou et al., starting from dibenzoylated diﬂu-
ororibose (Scheme 24), after deprotection.21 Pure gemcitabine was
then obtained by selective crystallisation.
The optimisation of the anomeric selectivity has been thor-
oughly investigated.41 It was found that lowering the temperaturein the mesylation reaction favoured formation of the a-mesylate.
At 19 C a 2:1 a/b ratio is obtained while a 4.4:1 a/b ratio was ob-
tained when the reaction is carried out at 83 C. No mention is
made of the effect the lowered temperature has upon the yield of
the reaction. Alternatively, b-mesylate could be equilibrated by
reaction with N,N-dimethylbenzylammonium methanesulfonate
at reﬂux temperature, to obtain a 2.3:1 a/bmixture of mesylates.41
While initial investigations into the mesylate displacement
gave a 1:1 mixture of protected nucleoside 98 regardless of the
anomeric ratio of mesylate 97,21 further investigation did give ano-
merically enriched b-nucleoside 98 starting from a-enriched
mesylate 97.41 Starting from the a-anomer, the best reported
method was the use of bis-silylated cytosine in anisole at 115 C,
yielding 79.5% of the protected nucleoside 98 as a 7.3:1 b/a mix-
O OH
F
FPhBzO
BzO
O OMs
F
FPhBzO
BzO
MsCl, Et3N
DCM
(83%)
then 2N HCl,
recryst from EtOH
(55%)100 (2.5:1 α/β)44 101 (35:1 β/α)
TMSOTf,
toluene,
reflux; O
F
FPhBzO
BzO N
N
NH2
O O
F
FHO
HO N
N
NH2
ONH3
MeOH
(89%)
1
(97% purity)
N
N
NHTMS
OTMS
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K. Brown et al. / Carbohydrate Research 387 (2014) 59–73 69ture. Alternatively nucleoside 98 could be synthesised with very
high (>14:1 b/a) anomeric selectivity when treated with bis-silyl-
cytosine in MeCN at 75 C in the presence of caesium sulfate or
barium triﬂate, however with a signiﬁcant reduction in yield
(25%).
A later patent from Chou42 describes the development of a sol-
ventless protocol for nucleobase addition. Interestingly, while
starting from the b-mesylate, displacement with silylated nucleo-
base gave predominantly the a-nucleoside (1:6–7 b/a ratio); from
the a-mesylate, the b-nucleoside was the major anomer, but in
lower ratios (up to 4:1 b/a). Kjell43 described that addition of cer-
tain salts in the glycosylation reaction increased the anomeric
selectivity. The best selectivity (14.9:1 b/a) was obtained with
the use of Cs2SO4, but with a poor yield of 24%. Use of the caesium
salt of triﬂic acid however, furnished a 6.7:1 b/a mixture of the
protected nucleoside 98 in 70% yield. It should be noted that in
these cases pure a-mesylate 97 was employed.
The anomeric ratio could also be improved by using a carbam-
oyl protecting group at the 3-position. For example, nucleobase
introduction with 99 (Fig. 2) led to a b/a ratio of around 1.5:1, com-
pared to a 1:1.5 ratio when the corresponding dibenzoate 97 is
used under the same conditions.44
Some of the protecting groups that were introduced to separate
the diastereomers arising from the Reformatsky reaction proved
also useful to separate the nucleoside anomers by crystallisation.25
For example, the 4-phenylbenzoate protected diﬂuororibose deriv-
ative 44 (Scheme 25). Mesylation led to a 1:2.5 b/a ratio of ano-
mers. Nucleobase introduction yielded a 1.8:1 b/a ratio of
anomers which upon nucleobase deprotection and recrystallisa-
tion yielded 101 as a 35:1 mixture in favour of the desired b-ano-
mer. Ester cleavage then leads to gemcitabine.O
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Scheme 26. Nucleobase addition b2.4.2. Tosylate leaving group
The crystalline lactone 45 (see 2.2.3.3, Scheme 10) was reduced
with lithium tri-t-butoxyaluminium hydride,26 and then directly
converted to the crystalline anomeric mixture of tosylate 102
(Scheme 26). Interestingly, the analogous mesylate was found to
be an oil. It is reported that the base employed in the tosylation
has an effect upon the anomeric ratio of the resultant tosylate;
however, no anomeric ratios are given. In any case, a 1:1 mixture
of anomers 103 was obtained regardless of the anomeric composi-
tion of the tosylate, which agrees with Chou’s results on their mes-
ylate,21 in an impressive, almost quantitative yield. The fact that a
pure mixture of solid tosylate anomers could be obtained allowed
the use of just 1 equiv of the expensive TMSOTf promotor for the
nucleobase introduction.
The unstable 103was not isolated, but hydrolysed to give the N-
acetyl protected cytidine derivative 104. The a-anomer was found
to precipitate from the reaction mixture, allowing its removal by
ﬁltration, giving the desired b-anomer. This material was subse-
quently deprotected with NH3 and converted to the gemcitabine
HCl salt. Recrystallisation from acetone/water furnished the gem-
citabine HCl salt with a purity of 99.8%.
A variation on this process was published by Zelikovitch et al.,45
where employing a different solvent combination after nucleobase
introduction caused precipitation of both anomers (Scheme 27). In
this way a mixture of 104was obtained (99% yield) containing 73%
b-anomer and 12% a-anomer. After deprotection of the cinnamoyl
groups, recrystallisation from acetone/water, provided the b ano-
mer of gemcitabineHCl in 99.6% purity.
2.4.3. Ester leaving groups
Born et al. reported the use of acetate as a leaving group for the
uracil introduction (Scheme 28).46 Treatment of acetate 106 withTMSOTf, DCE
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70 K. Brown et al. / Carbohydrate Research 387 (2014) 59–73bis-silyluracil in the presence of SnCl4 yielded the protected nucle-
oside 98 as a 5:1 b/a anomeric mixture. This anomeric ratio could
be further enhanced by trituration to a 95% de.
In a similar vein, Chen reported a nucleobase introduction from
the tri-O-benzoate 67 (Scheme 29),32 leading to 98 in excellent
yield and anomeric ratio after a crystallisation procedure.
2.4.4. Bromide leaving group
Chang reported that nucleobase introduction was possible in
excellent yield starting from the corresponding a-diﬂuororibosyl
bromide donor 108 (Scheme 30).24a,46 While the optimisation of
the nucleobase introduction reaction led to an excellent anomeric
ratio, revealing some interesting mechanistic aspects of the reac-
tion in the process, anomerically pure gemcitabine was ultimately
obtained by a crystallisation process involving a hemihydrate form.
A key feature of the process was the synthesis of the donor in
anomerically pure form. The required bromide was obtained by
ﬁrst phosphorylating the crude lactol 44 to give theO
BzO
BzO
OBz
F
F
67
SnCl4, MeCN
reflux, 12 h
then add EtOAc;
aq NaHCO3 wash;
concentrate and crystallise
O
BzO
BzO
9
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(83%)
N
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NHTMS
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Scheme 29. Nucleobase introductiondiphenylphosphate 107 as a 1:10.8 a/b mixture. Recrystallisation
from IPA/water enhanced this ratio to >98:2 a/b. However, this
anomeric enhancement was ultimately unnecessary as the ano-
meric purity of the phosphate 107 had no effect upon the anomeric
selectivity of the subsequent bromination step. The bromide 108
was obtained as a 10.8:1 a/b mixture, which again could be en-
hanced by recrystallisation from IPA to >99.7:0.3 a/b. Interestingly,
the 4-phenyl benzoate group, employed to assist the separation of
diastereomers obtained in the Reformatsky reaction as described
above, proved also essential for the crystallisation process of 108,
as the corresponding dibenzoate is an oil.
Initial studies found protected nucleoside 101 to be formed as a
1:1 anomeric mixture, when bromide 108was reacted with disilyl-
cytosine. This total lack of anomeric selectivity was presumed to be
due to anomerisation of the bromide 108, either via an SN1 process,
or via an SN2 reaction promoted by TMSBr formed in the reaction
mixture. A control experiment involving treatment of a-108 with
TMSBr indeed led to the formation of a small amount of b-anomer.
Even if only a small amount of b-anomer was observed, its greater
reactivity would explain the formation of a large amount of a-101.
Indeed when the TMSBr was removed from the reaction mixture
via continuous distillation, using heptane as a co-solvent, the ano-
meric selectivity increased to 5.5:1 b/a, a signiﬁcant improvement.
In addition, a non-polar solvent system was also utilised to mini-
mise the SN1 process. Deprotection of the 5.5:1 b/a mixture of
101 with NH3, and recrystallisation from water yielded gemcita-
bine in greater than 99.8% anomeric purity, either as gemcitabine
hemihydrate—if the mixture was stirred during the crystallisa-
tion—or as gemcitabine dihydrate—if it was not stirred.
In their patent application of the same synthesis it was also dis-
closed that the a small amount of additional silyl donor (N,O-
bis(trimethylsilyl)acetamide, 1% v/v) to the nucleobase addition
reaction further enhances the anomeric ratio of 101 to 14:1 b/a,
however yield was not given.
2.4.5. Iodide leaving group
Chou et al. demonstrated the possibility for nucleobase intro-
duction by employing iodide as the leaving group. In their patent,O
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riched 3,5-di-O-benzoyl protected donor proceeded with full con-
version, and in a modest 1.13:1 b/a ratio.48 Chu et al. managed
to increase the anomeric ratio by employing >1 equiv of silver car-
bonate as additive (Scheme 31, conditions A).49 The iodide 109 is
synthesised from the corresponding lactol via the mesylate, orvia direct iodination using I2 and PPh3 in dichloromethane. Though
the anomeric ratio of the donor is not speciﬁed, the 5.6:1 b/a-selec-
tivity for the nucleobase introduction is explained via invoking an
SN1 type mechanism whereby the formation of the [destabilised]
oxonium intermediate is facilitated by Ag(I), with stabilisation pro-
vided by neighboring group participation of the 3-O-benzoate
O
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Scheme 33. Linear nucleobase synthesis.37
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Scheme 35. Recycling of 2-deoxy-2,2-diﬂuororibose from the a-anomer of gemcitabine.38
72 K. Brown et al. / Carbohydrate Research 387 (2014) 59–73group (110). Hence the bottom face of the ribose ring is blocked for
nucleophilic attack thereby enhancing the formation of the b-ano-
mer. Remarkably, this reaction is reported to proceed in quantita-
tive yield.
Chien et al. used a different activating system to achieve the for-
mation of 111 (Scheme 31, conditions B).50 By using 1 equiv of an
oxidant, released iodide is oxidised to I2, which is thought to assist
oxonium ion formation through stabilisation of the iodide leaving
group as I3 . Though no yield is given, very high anomeric ratios
of 111 were obtained. This method does not work well starting
from the corresponding bromide or chloride donor.
Nucleobase introduction starting from the mesylate 112 in the
presence of NaI also gives an increased b-ratio.13 Presumably this
reaction proceeds via the corresponding anomeric iodide, and
may involve neighboring group participation as well.
2.4.6. Trichloroacetimidate leaving group
Maikap et al.51 and Vishnujant et al.52 have both reported the
use of trichloroacetimidate as a leaving group in the nucleobase
introduction step (Scheme 32). The trichloroacetimidate donor
115 was prepared from the lactol, and nucleobase introduction
was reported to proceed in good yields, but no anomeric ratio
was speciﬁed.
2.5. Nucleobase introduction—linear nucleobase synthesis
The nucleobase can also be introduced via a linear sequence
from the corresponding glycosyl amine derivative. Despite thedifﬁculties in introducing the nucleobase via a convergent pathway
(see above), very few reports involving this alternative are
available.
2.5.1. From the anomeric acetate
Glycosylation of peracetylated 2-deoxy-2,2-diﬂuororibose 91
(Scheme 33) with N,N-bistrimethylsilyl-((Z)-2-cyanovinylurea)
118, synthesised from the corresponding cyanovinylurea, under
Lewis-acid activation led to the nucleoside precursor 119.37 Base-
mediated cyclisation resulted in cytosine ring formation with con-
comitant protecting group removal. Though no anomeric ratio was
provided, silica gel based chromatography led to gemcitabine 1 in
12% overall yield.
2.5.2. Synthesis of the anomeric amine precursor
An alternative way for the synthesis of pyrimidine nucleosides
employs anomeric aminoglycoside derivatives as starting material.
Hertel et al. disclosed the synthesis of the primary aminoglycoside
121 (Scheme 34) as suitable precursor for a linear gemcitabine syn-
thesis.53 Nucleophilic substitution of mesylate 7 by azide led to
120 in excellent yield. The synthesis of the analogous benzyl pro-
tected aminoglycoside was also reported. It was found that the
azide introduction proceeded with inversion of conﬁguration:
when the a-mesylate was used, the b-azide was isolated in 76%
yield; starting from the b-mesylate, the a-azide was isolated in
73% yield. Azide reduction to the amine 121 then proceeded in
near quantitative yield, and a 1:1 anomeric ratio was obtained
regardless of the conﬁguration of the starting azide.
K. Brown et al. / Carbohydrate Research 387 (2014) 59–73 732.6. Recycling of the a-anomer
Given no fully selective nucleobase introduction method has
been developed so far, all current syntheses yield a quantity of
undesired a-anomer of gemcitabine, and a number of methods
have been developed to convert this byproduct into gemcitabine,
or at least to recover the valuable diﬂuororibose.
Britton showed that pure a-anomer could be isomerised to the
b-anomer by treatment with a hydroxide base in an anhydrous
alcohol solvent, up to a ratio of 35:65 a:b.54
Nagarajan, from the Lilly labs, developed a process to recover
2-deoxy-2,2-diﬂuororibose from the unwanted a-anomer of gem-
citabine (Scheme 35).38 In order to remove the nucleobase group
by hydrolysis at the anomeric centre, a process disfavoured by the
presence of the ﬂuorination at the C2 position, the pyrimidine ring
was ﬁrst partially hydrogenated using a PtO2 catalyst at medium
hydrogen gas pressure to give 122. This then enabled acid-catalysed
hydrolysis using strong mineral acid at high temperature (steam
bath), yielding the 2-deoxy-2,2-diﬂuororibose sugar 14. Puriﬁca-
tion is necessary, and this can be achieved by column chromatogra-
phy and recrystallisation (80% yield from 1a), or alternatively, by
acetylating the crude reaction mixture to give the triacetate 15,
followed by deprotection and recrystallisation. However, this
second procedure leads to diﬂuororibose in only 28% overall
yield.
2.7. Conclusion
This review illustrates how the quest for an efﬁcient, scalable
synthesis of gemcitabine has spurned enormous synthetic efforts
towards 2-deoxy-2,2-diﬂuororibose and its nucleobase introduc-
tion. It provides a nice overview of the different strategies for
CF2-introduction in a sugar moiety: a building block approach,
electrophilic a-ﬂuorination of esters (lactones) and nucleophilic
ﬂuorination of ketones. Finally, it is shown how diﬂuorination at
a sugar 2-position necessitates less conventional methods for
nucleobase introduction. The review also gives a taste of how dif-
ferent protecting groups can be used to ﬁnd conditions to separate
diastereomers by crystallisation. Despite all the efforts, there is still
scope for increasing selectivities and yields, and with the recent
expiration of the Lilly gemcitabine patent, it is certain that further
research to that effect will continue.
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